

How to Complete a Risk Assessment for si/shRNA Experiments in Animals and Cell Culture

1. **Agent:** siRNA specific for [insert species]. Discuss how the siRNA will be dosed: viral vector, nanoparticle, plasmid, liposome, etc.
2. **Synonym:** Gene silencing
3. **Containment Requirements:** Usually BSL-1 and chemical hygiene practices, containment equipment and facilities for all activities involving non-virus dosing. For virus-vectored siRNA, BSL-2 practices including biological safety cabinets are recommended. Centrifuge safety precautions, secondary containers for transport between incubator and BSC. Keep hands away from the eyes, nose and mouth in order to avoid potential exposure of the mucous membranes; eye goggles or face shields may assist in accomplishing this objective.
4. **siRNA dosing precautions:** Systemic *in vivo* siRNA delivery in mammals was first demonstrated using hydrodynamic tail vein injections in mice. In this procedure, unmodified siRNAs are rapidly injected into the tail vein in a large volume of aqueous solution, resulting in localization within hepatocytes. Although not clinically relevant, this procedure does permit gene function and drug target validation studies within the rodent liver, until more effective delivery technologies are developed. In support of this technique, Song and colleagues found that hydrodynamic injection of a Fas siRNA resulted in silencing of Fas in mouse hepatocytes for a period of 10 days. Similarly, hydrodynamic tail vein injection of a caspase 8 siRNA protected mice against acute liver failure induced by Fas antibody or expression of Fas ligand. More recently, low volume, normal pressure intravenous delivery of a modified siRNA targeting apolipoprotein B in mice resulted in gene silencing in the liver and jejunum. The siRNA was conjugated with cholesterol to provide targeted delivery, and included backbone and sugar modifications to enhance serum stability. Although route of administration is an important variable, systemically administered naked nucleic acids generally accumulate in the organs of the reticuloendothelial system (RES) such as the liver, lung, spleen, and kidneys (43), and recent reports suggest that siRNAs also behave similarly (44–46). Braasch et al. (44) first showed that siRNAs in mice accumulate in the liver and kidneys following systemic administration. Additional studies (45, 46) also showed that naked siRNAs accumulate in the kidneys of mice and are detectable in the urine as early as 5 minutes after i.v. injection. Taken together, these studies suggest that siRNAs behave as typical macromolecules of less than 50 kDa and 6 nm, in that they are susceptible to glomerular filtration in the kidney and excretion in the urine. (Akhtar et al, Journal of Clinical Investigation V117 N12 December 2007) The use of sharps should be minimized. Safe-sharp technology is highly recommended during animal dosing.
5. **Spills:** If non-virus vectored, cleanup per the chemical hygiene plan.
6. **Biohazardous Waste:** Collect in double red bags and transport in a rigid container.
7. **Approved Disinfectants:**
 - i. Non-virus vectored siRNA: soap and water
 - ii. Virus-vectored; disinfectants appropriate for the virus.

- 8. Disposal:** Non-virus vectored, as a chemical. Virus-vectored: Decontaminate before disposal; steam sterilization, incineration, chemical disinfection.
- 9. Storage:** Store as per the chemical hygiene plan.
- 10. Pathogenicity:** Mucous membranes, ingestion, broken skin and injection. Reasons can be sharps contact, failure to wash hands, skin contamination from dirty gloves or work surfaces.
- 11. Modes of Transmission:** Liposomes and plasmids may cross the cell membrane of individual cells. If the gene target is present, it could result in silencing. Liposomes and plasmids are not infectious; once integrated into cells, they do not reproduce.
- 12. Length of gene expression:** Non-viral vectored RNA silencing is transient, lasting between 5-7 days in rapidly dividing cells; silencing can last up to 3 weeks in non-dividing cells. (Bartlett et al, Nucleic Acids Research V 34, N 1 Pp. 322-333)
- 13. Communicability:** Not communicable.
- 14. Medical surveillance and clinical treatment procedure:** No medical surveillance is required. GOH Clinical Operating Procedure "Lentivirus Vectors" must be listed on risk assessment if used to vector siRNA.
- 15. Stability in Environment:** Samples shipped as dried pellets are stable at room temperature for 2-4 weeks. Neither repeated freeze/thaw cycles, extended incubations (over 1 year at 21°C), nor shorter incubations at high temperatures (up to 95°C) have any effect on siRNA integrity as measured by non-denaturing polyacrylamide gel electrophoresis and functional activity assays. Degradation was also not observed following exposure to hair or skin at 37°C. However, incubation in fetal bovine or human sera at 37°C led to degradation and loss of activity. Therefore, siRNA in the bloodstream is likely inactivated, thereby limiting systemic exposure (Oligonucleotides. Dec 2008; 18(4): 345–354).
- 16. siRNA concentration, dosage per experiment:** State your stock concentration, and the amount used per experiment or kg animal weight.
- 17. siRNA shedding from animals:** Animals will not shed siRNA if dosed by intravenous route. For viral vector dosing route, refer to specific viral vector risk assessment.
- 18. Transgene Information:** Discuss effects of transgene on animal or cell line. A good source for understanding the transgene being silenced or over-expressed is GENE CARDS (<http://www.genecards.org/>). A snapshot of a sample gene card is shown below:

GeneCards®
The Human Gene Compendium

WELFORD
WELDMANN INSTITUTE OF SCIENCE

with **LifeMap SCIENCES**
a division of

Free for academic non-profit institutions. All other users need a commercial license from LifeMap Sciences, Inc.

Home GeneCards Guide Suite Terms and Conditions About Us User Feedback Mirror sites

Set Analyses: [GeneCards](#) [GeneDecks](#) keyword(s) [Advanced Search](#)

TNFRSF10B Gene
protein-coding [GFEs: 73](#)
GCID: GC08M022877

Tumor Necrosis Factor Receptor Superfamily, Member 10b

[ESCMID Microbiology & Infectious Diseases Congress](#)

M Antibodies / cDNA / RNA / Proteins & Enzymes / Assays & Kits / Pathways

U [UniProt](#) [Gene Network](#) [TFBS](#) [PCR Arrays](#) [Pharos](#) [CMP](#) [KEP](#)

[88 related diseases at MalaCards](#)

ORIGENE Proteins / Antibodies / Assays / Genes / shRNA / Primers

GenScript Genes / Proteins / Antibodies / Peptides

Jump to Section...

Aliases
for TNFRSF10B gene
(According to [HGNC](#), [Entrez Gene](#), [UniProt/Swiss-Prot](#), [UniProt/TrEMBL](#), [OMIM](#), [GeneLoc](#), [Ensembl](#), [OMIM](#), [mRBase](#), [tRNAdb](#), [HinvDB](#), [NCBI](#), [NONCODE](#) and/or [tRNAdb](#))
[About This Section](#)

This gene clusters with an RNA gene
Subcategory (RNA class): lncRNA

[Quality score](#) for the [ORFQUL](#) clustered with this gene is 3

Aliases
Tumor Necrosis Factor Receptor Superfamily, Member 10b^{1,2}

DR5 ^{1,2}	TRICK2B ²
TRAILR2 ^{1,2,3}	Apoptosis Inducing Protein TRICK2A/2B ²
Death Receptor 5 ^{1,2}	Apoptosis Inducing Receptor TRAIL-R3 ²
KILLER ^{1,2}	Cytotoxic TRAIL Receptor-2 ²
TRAIL-R2 ^{1,2}	Death Domain Containing Receptor For TRAIL/Apo-2L ²
TRICK2L ^{1,2}	Fas-Like Protein ²
ZTNFR5 ^{1,2}	P53-Regulated DNA Damage-Inducible Cell Death Receptor/Killer ²
TNF-Related Apoptosis-Inducing Ligand Receptor 2 ^{1,2}	Tumor Necrosis Factor Receptor Superfamily Member 10B ²
CD262 ²	Tumor Necrosis Factor Receptor-Like Protein ZTNFR5 ²
KILLER/DR5 ²	CD262 Antigen ²
TRICK2A ²	TRAIL Receptor 2 ²

External Ids: [HGNC: 11905](#) [Entrez Gene: 8799](#) [Ensembl: ENSG00000120889](#) [OMIM: 603613](#) [UniProtKB: Q14763](#)

ORFQUL members:
[NONCODE](#) [nc407670](#) [mprosis](#)

[Export aliases for TNFRSF10B gene to outside databases](#)

Previous GC Identifiers: GC08M022647 GC08M023231 GC08M022899 GC08M022933 GC08M021422

To better understand potential human outcomes from accidental silencing, you can see if information exists in the JAX Mouse Genome Informatics: (<http://www.informatics.jax.org/batch>). Enter the gene designation, and then look to see if a mouse knockout phenotype exists. If so, add that information to the risk assessment.

MGI Celebrating 25 years with us

Keywords, Symbols, or IDs **Quick Search**

[About](#) [Home](#) [Genes](#) [Phenotypes](#) [Human Disease](#) [Expression](#) [Recombinases](#) [Function](#) [Strains / SNPs](#) [Homology](#) [Pathways](#) [Tumors](#)

[Search](#) [Download](#) [More Resources](#) [Submit Data](#) [Find Mice \(IMSR\)](#) [Analysis Tools](#) [Contact Us](#) [Browsers](#)

MGI Batch Query

Click to hide search

Search **Reset** Download gene/marker data for a batch of IDs or symbols.

Input	Output
<p>Type: Search all input types</p> <p>Source:</p> <p>Enter Text <input type="text"/> Upload File <input type="button"/></p> <p>ID/Symbols List:</p> <p>*tab, space, and newline separated ids.</p>	<p>Gene Attributes:</p> <p><input checked="" type="checkbox"/> Nomenclature <input type="checkbox"/> Genome Location <input type="checkbox"/> Ensembl ID</p> <p><input type="checkbox"/> Entrez Gene ID <input type="checkbox"/> VEGA ID</p> <p>Additional Information:</p> <p><input type="radio"/> Gene Ontology (GO) <input type="radio"/> Mammalian Phenotype (MP) <input type="radio"/> Human Disease (OMIM)</p> <p><input type="radio"/> Alleles <input type="radio"/> Gene Expression <input type="radio"/> RefSNP ID</p> <p><input type="radio"/> GenBank/RefSeq ID <input type="radio"/> UniProt ID <input checked="" type="radio"/> None</p>

Search **Reset**

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc

[Using These Resources](#)
[Additional Information](#)
[Webinars, Tutorials & Creative Commons](#)
 Send questions and comments to [user support](#).

last database update: 09/09/2014
MGI 5.19

The Jackson Laboratory

You must discuss the potential effects due to accidental worker exposure. If unknown, state that. Is the gene sequence or siRNA specific to animals, humans or could it affect both?